Research programme: HIV gene therapy - AGC Biologics /Takara Bio
Alternative Names: Chim3; F12-Vif; MM-F12Latest Information Update: 29 Oct 2020
At a glance
- Originator MolMed; Takara Bio
- Class Gene therapies; Polynucleotides; Proteins
- Mechanism of Action Gene transference
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity No
Highest Development Phases
- No development reported HIV infections
Most Recent Events
- 04 Nov 2017 No recent reports of development identified for research development in HIV-infections in Japan (Parenteral)
- 29 Jun 2009 Preclinical development is ongoing in Japan
- 29 Jun 2009 Chim3 is available for licensing worldwide (http://www.molmed.com)